Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment

Virology

Volumn 230, Issue 2, 1997, Pages 155-166

  Power, Ultan F ^a   Plotnicky Gilquin, Hélène ^a   Huss, Thierry ^a   Robert, Alain ^a   Trudel, Michel ^b   Ståhl, Stefan ^c   Uhlén, Mathias ^c   Nguyen, Thien Ngoc ^a   Binz, Hans ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITÉ LAVAL   (Canada)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; RECOMBINANT PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION;

ANIMALIA; ESCHERICHIA COLI; GOSSYPIUM HIRSUTUM; MURINAE; PROKARYOTA; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RODENTIA; SIGMODON; SYNCYTIAL VIRUS;

EID: 0030968130     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8465     Document Type: Article

References (64)

1. Åkerlind-Stopner B., Utter G., Mufson M. A., Orvell C., Lerner R. A., Norrby E. A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop. J. Virol. 64:1990;5143-5148.
2. Alexander S., Elder J. H. Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science. 226:1984;1328-1330.
3. Alwan W. H., Kozlowska W. J., Openshaw P. J. M. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:1994;81-89.
4. Cane P. A., Matthews D. A., Pringle C. R. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. J. Gen. Virol. 72:1991;2091-2096.
5. Cane P. A., Pringle C. R. Evolution of subgroup A respiratory syncytial virus: Evidence for progressive accumulation of amino acid changes in the attachment protein. J. Virol. 69:1995;2918-2925.
6. Cannon M. J., Stott E. J., Taylor G., Askonas B. A. Clearance of persistent respiratory syncytial virus infection in immunodeficient mice following transfer of primed T cells. Immunology. 62:1987;133-138.
7. Chanock R. M., Parrott R. H., Connors M., Collins P. L., Murphy B. R. Serious respiratory tract disease caused by respiratory syncytial virus: Prospects for improved therapy and effective immunization. Pediatrics. 90:1992;137-143.
8. Collins P. L., McIntosh K., Chanock R. M. Fields Virology. 1996;Lippincott-Raven, Philadelphia. p. 1313-1351.
9. R. M. Dougherty, 1964, Techniques in Experimental Virology, R. J. C. Harris, 169, 223, Academic Press, San Diego.
10. Elango N., Prince G. A., Murphy B. R., Venkatesan S., Chanock R. M., Moss B. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc. Natl. Acad. Sci. USA. 83:1986;1906-1910.
11. Elder J. H., McGee J. S., Alexander S. Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response. J. Virol. 57:1986;340-342.
12. Furze J., Wertz G., Lerch R., Taylor G. Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus. J. Gen. Virol. 75:1994;363-370.
13. Garcia O., Martin M., Dopazo J., Arbiza J., Frabasile S., Russi J., Hortal M., Perez-Brena P., Martinez I., García-Barreno B., Melero J. A. Evolutionary pattern of human respiratory syncytial virus (subgroup A): Cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J. Virol. 68:1994;5448-5459.
14. Garcia-Beato R., Martinez I., Franci C., Real F. X., García-Barreno B., Melero J. A. Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein. Virology. 221:1996;301-309.
15. Graham B. S., Tang Y.-W., Gruber W. C. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. J. Infect. Dis. 171:1995;1468-1474.
16. Hancock G. E., Speelman D. J., Frenchick P. J., Mineo-Kuhn M. M., Baggs R. B., Hahn D. J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine. 13:1995;391-400.
17. Hancock G. E., Speelman D. J., Heers K., Bortell E., Smith J., Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:1996;7783-7791.
18. Hemming V. G., Prince G. A., Groothuis J. R., Siber G. R. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:1995;22-33.
19. Johnson P. R. Jr., Olmsted R. A., Prince G. A., Murphy B. R., Alling D. W., Walsh E. E., Collins P. L. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: Evaluation of the contributions of F and G glycoproteins to immunity. J. Virol. 61:1987;3163-3166.
20. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:1968;422-434.
21. Klaus G. G. B., Pepys M. B., Kitajima K., Askonas B. A. Activation of mouse complement by different classes of mouse antibody. Immunology. 38:1979;687-695.
22. Kniskern P. J., Hagopian A., Burke P., Schultz L. D., Montgomery D. L., Hurni W. M., Ip C. Y., Schulman C. A., Maigetter R. Z., Wampler D. E., Kubek D., Sitrin R. D., West D. J., Ellis R. W., Miller W. J. Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation. Vaccine. 12:1994;1021-1025.
23. Lounsbach G. R., Bourgeois C., West W. H. L., Robinson J. W., Carter M. J., Toms G. L. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli. J. Gen. Virol. 74:1993;2559-2565.
24. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
25. Makrides S. C., Nygren P.-Å., Andrews B., Ford P. J., Evans K. S., Hayman E. G., Adari H., Levin J., Uhlén M., Toth C. A. Extendedin vivo. J. Pharmacol. Exp. Ther. 277:1996;534-542.
26. Manning D. S., Leong J. C. Expression inEscherichia coli. Virology. 179:1990;16-25.
27. Martin-Gallardo A., Fien K. A., Hu B. T., Farley J. F., Seid R., Collins P. L., Hildreth S. W., Paradiso P. R. Expression of the F glycoprotein gene from human respiratory syncytial virus inEscherichia coli: Virology. 184:1991;428-432.
28. Martin-Gallardo A., Fleischer E., Doyle S. A., Arumugham R., Collins P. L., Hildreth S. W., Paradiso P. R. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 74:1993;453-458.
29. Mazumder B., Adhikary G., Barik S. Bacterial expression of human respiratory syncytial viral phosphoprotein P and identification of Ser237 as the site of phosphorylation by cellular casein kinase II. Virology. 205:1994;93-103.
30. Mufson M. A., Orvell C., Rafnar B., Norrby E. Two distinct subtypes of human respiratory syncytial virus. J. Gen. Virol. 66:1985;2111-2124.
31. Munoz J. L., McCarthy C. A., Clark M. E., Hall C. B. Respiratory syncytial virus infection in C57BL/6 mice: Clearance of virus from the lungs with virus-specific cytotoxic T cells. J. Virol. 65:1991;4494-4497.
32. Murby M., Samuelsson E., Nguyen T. N., Mignard L., Power U., Binz H., Uhlén M., Ståhl S. Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 230:1995;38-44.
33. Murphy B. R., Sotnikov A., Paradiso P. R., Hildreth S. W., Jenson A. B., Baggs R. B., Lawrence L., Zubak J. J., Chanock R. M., Beeler J. A. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine. 7:1989;533-540.
34. Murphy B. R., Sotnikov A. V., Lawrence L. A., Banks S. M., Prince G. A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 8:1990;497-502.
35. Murphy B. R., Hall S. L., Kulkarni A. B., Crowe J. E. Jr., Collins P. L., Connors M., Karron R. A., Chanock R. M. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:1994;13-36.
36. Nguyen T. N., Uhlén M., Ståhl S. Uhlén M., Hornes E., Olsvik O. Advances in Biomagnetic Separation. 1994;73-78 Eaton, Natick.
37. Nguyen T. N., Gourdon M. H., Hansson M., Robert A., Samuelson P., Libon C., Andreoni C., Nygren P.-Å., Binz H., Uhlén M., Ståhl S. Hydrophobicity engineering to facilitate surface display of heterologous gene products in Staphylococcus xylosus. J. Biotech. 42:1995;207-219.
38. Nygren P.-Å., Eliasson M., Palmcrantz E., Abrahmsen L., Uhlén M. Analysis and use of the serum albumin binding domains of streptococcal protein G. J. Mol. Recogn. 1:1988;60-74.
39. Nygren P.-Å., Flodby P., Andersson R., Wigzell H., Uhlén M. Chanock R. M., Brown F., Ginsberg H. S., Lerner R. A. Vaccines 91, Modern Approaches to Vaccine Development. 1991;363-368 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
40. Oien N. L., Brideau R. J., Walsh E. E., Wathen M. W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine. 12:1994;731-735.
41. Olmsted R. A., Murphy B. R., Lawrence L. A., Elango N., Moss B., Collins P. L. Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus. J. Virol. 63:1989;411-420.
42. G. Palladino, L. York, S. Adams, D. Giorgio, E. Mishkin, 1995, Longevity of immunity against respiratory syncytial virus induced in mice by two vaccine candidate strains. ASV, 14th Annual Meeting, Austin, TX P13-1, 129.
43. Palomo C., García-Barreno B., Peñas C., Melero J. A. The G protein of human respiratory syncytial virus: Significance of carbohydrate side-chains and the C-terminal end to its antigenicity. J. Gen. Virol. 72:1991;669-675.
44. Piedra P. A., Wyde P. R., Castleman W. L., Ambrose M. W., Jewell A. M., Speelman D. J., Hildreth S. W. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine. 11:1993;1415-1423.
45. Prince G. A., Hemming V. G., Horswood R. L., Baron P. A., Chanock R. M. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J. Virol. 61:1987;1851-1854.
46. Routledge E. G., Willcocks M. M., Samson A. C., Morgan L., Scott R., Anderson J. J., Toms G. L. The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. J. Gen. Virol. 69:1988;293-303.
47. Rueda P., García-Barreno B., Melero J. A. Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations). Virology. 198:1994;653-662.
48. Sjölander A., Nygren P.-Å., Ståhl S., Berzins K., Uhlén M., Perlmann P., Andersson R. The serum albumin-binding region of streptococcal protein G: A bacterial fusion partner with carrier-related properties. J. Immunol. Methods. 201:1997;115-123.
49. Skehel J. J., Stevens D. J., Daniels R. S., Douglas A. R., Knossow M., Wilson I. A., Wiley D. C. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl. Acad. Sci. USA. 81:1984;1779-1783.
50. Speigelberg H. L. Dixon F. J., Kunkel H. G. Advances in Immunology. 1974;259-294 Academic Press, New York.
51. Srivastava A. K., Morita K., Matsuo S., Tanaka M., Igazashi A. Japenese encephalitis virus fusion protein with protein A expressed inEscherichia coli. Microbiol. Immunol. 35:1991;863-870.
52. Srivastava A. K., Putnak J. R., Warren R. L., Hoke C. H. Jr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made inEscherichia coli. Vaccine. 13:1995;1251-1258.
53. Ståhl S., Sjölander A., Nygren P.-Å., Berzins K., Perlmann P., Uhlén M. A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of thePlasmodium falciparum. J. Immunol. Methods. 124:1989;43-52.
54. Stott E. J., Ball L. A., Young K. K., Furze J., Wertz G. W. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J. Virol. 60:1986;607-613.
55. Stott E. J., Taylor G., Ball L. A., Anderson K., Young K. K., King A. M., Wertz G. W. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:1987;3855-3861.
56. Sullender W. M., Anderson K., Wertz G. W. The respiratory syncytial virus subgroup B attachment glycoprotein: Analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge. Virology. 178:1990;195-203.
57. Sullender W. M., Mufson M. A., Anderson L. J., Wertz G. W. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J. Virol. 65:1991;5425-5434.
58. Taylor G., Stott E. J., Bew M., Fernie B. F., Cote P. J., Collins A. P., Hughes M., Jebbett J. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology. 52:1984a;137-142.
59. Taylor G., Stott E. J., Hughes M., Collins A. P. Respiratory syncytial virus infection in mice. Infect. Immun. 43:1984b;649-655.
60. Taylor G., Stott E. J., Hayle A. J. Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus. J. Gen. Virol. 66:1985;2533-2538.
61. Trudel M., Nadon F., Seguin C., Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology. 185:1991;749-757.
62. Vaux-Peretz F., Chapsal J. M., Meignier B. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine. 10:1992;113-118.
63. Wagner D. K., Muelenaer P., Henderson F. W., Snyder M. H., Reimer C. B., Walsh E. E., Anderson L. J., Nelson D. L., Murphy B. R. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections. J. Clin. Microbiol. 27:1989;589-592.
64. Walsh E. E., Hall C. B., Briselli M., Brandriss M. W., Schlesinger J. J. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J. Infect. Dis. 155:1987;1198-1204.